APP 詳細
Molecule Name
Beta amyloid A4 protein
分子の別称
ABPP,APPI,Amyloid-beta A4 protein
Drug Development Progress
治験薬の数52
市販薬剤の数13
研究＆開発段階Approved
ターゲットの別称
Beta-CTF，Amyloid Beta Precursor Protein，Cerebral Vascular Amyloid Peptide，Beta-Amyloid Precursor Protein，Amyloid-Beta A4 Protein，Beta-Amyloid Peptide，Alzheimer Disease，CTFgamma，ABETA，AAA，PN2，Amyloid beta-Peptides，Amyloid intracellular domain 57，APP，Amyloid intracellular domain 59，PN-II，Alpha-secretase C-terminal fragment，AICD-50，S-APP-alpha，A4，S-APP-beta，Alzheimer disease amyloid protein，Abeta40，Gamma-CTF(59)，Abeta42，Gamma-CTF(57)，Alpha-CTF，Amyloid intracellular domain 50，AID(59)，Gamma-CTF(50)，AID(57)，Beta-secretase C-terminal fragment，Amyloid-beta precursor protein，Amyloid precursor protein，AD1，AICD-57，Beta-APP42，APPI，Beta-APP40，AID(50)，CVAP，AICD-59，Amyloid Beta (A4) Precursor Protein，Peptidase Nexin-II，Protease Nexin-II，PreA4，ABPP，Testicular Tissue Protein Li 2，Beta-Amyloid Peptide(1-40)，Beta-Amyloid Peptide(1-42)，Amyloid Beta A4 Protein
バックグランド
Amyloid precursor protein (APP) is a type I integral membrane protein ubiquitously expressed in many tissues and concentrated in the synapses of neurons. It has three predominant splice variants: APP695, APP751, and APP770. The majority of APP is cleaved at the plasma membrane by the α-secretase in the non-amyloidogenic pathway. The amyloidogenic pathway starts with β-secretase cleavage by BACE1 on the N-terminal part of the Aβ domain, releasing sAPPβ from a membrane-anchored fragment named βCTF or C99, which is subsequently cleaved by γ-secretase to release Aβ.
APP 製品リスト
You Have Viewed 0 Of 0 Results
治験薬に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Buntanetap | ANVS-405; ANVS-401 | Phase 3 Clinical | Raptor Pharmaceutical | Alzheimer Disease; Chronic Traumatic Encephalopathy; Cognitive Dysfunction; Down Syndrome; Frontotemporal Dementia; Parkinson Disease | 詳細 |
| Gantenerumab | MAb-31; R-1450; RG-1450; R-04909832 | Phase 3 Clinical | Chugai Pharmaceutical Co Ltd | Alzheimer Disease; Dementia | 詳細 |
| Valiltramiprosate | BLU-8499; NRM-8499; ALZ-801 | Phase 3 Clinical | Alzheon Inc | Alzheimer Disease | 詳細 |
| Solanezumab | LY-2062430 | Phase 3 Clinical | Eli Lilly And Company | Alzheimer Disease; Cognition Disorders; Dementia | 詳細 |
| Tramiprosate | 3-APS; NC-531; NC-758 | Phase 3 Clinical | Bellus Health Inc | Alzheimer Disease; Glaucoma; Neurodegenerative Diseases; Stroke | 詳細 |
| Remternetug | LY-3372993; LY3372993 | Phase 3 Clinical | Eli Lilly And Company | Alzheimer Disease; Dementia | 詳細 |
| [F-18]Flornaptitril | [F-18]FDDNP; F-18-FNT-PET | Phase 3 Clinical | University Of California At Los Angeles | Alzheimer Disease; Chronic Traumatic Encephalopathy | 詳細 |
| F-18 Florbetazine | Phase 3 Clinical | Hta Co Ltd | Alzheimer Disease | 詳細 | |
| RP-902 | RP902; RP-902 | Phase 3 Clinical | Risen (Suzhou) Pharma Tech Co Ltd | Alzheimer Disease | 詳細 |
| Trontinemab | RO-7126209; RG-6102 | Phase 3 Clinical | F. Hoffmann-La Roche Ltd | Alzheimer Disease | 詳細 |
| GAL-101 | EG-030; GAL-101; MRZ-99030 | Phase 2 Clinical | Tel Aviv University Trust | Geographic Atrophy; Glaucoma | 詳細 |
| L-clausenamide | Phase 2 Clinical | Fuan Pharmaceutical (Group) Co Ltd, Guangzhou Nuohao Pharmaceutical Technology Co Ltd, Institue Of Materia Medica Chinese Academy Of Medical Science, Qingdao Huanghai Pharmaceutical Co Ltd | Cognitive Dysfunction; Dementia; Memory Disorders | 詳細 | |
| Crenezumab | MABT-5102-A; RG-7412; R-7412; RO-5490245 | Phase 2 Clinical | Ac Immune Sa | Alzheimer Disease | 詳細 |
| (-)-Epigallocatechin gallate | AB-4166 | Phase 2 Clinical | Charite Universitaetsmedizin Berlin | Alzheimer Disease; Colonic Neoplasms; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Frailty; Glaucoma, Open-Angle; Huntington Disease; Hypertension; Idiopathic Pulmonary Fibrosis; Inflammation; Insulin Resistance; Leukemia; Liver Cirrhosis; Lung Diseases, Interstitial; Multiple Sclerosis, Relapsing-Remitting; Muscular Dystrophy, Duchenne; Neoplasms; Obesity; Ocular Hypertension; Papillomavirus Infections; Parkinson Disease; Peripheral Nervous System Diseases; Prostatic Neoplasms; Uterine Cervical Diseases | 詳細 |
| 11C-BF-227 | 11C-BF-227; [11C]BF-227 | Phase 2 Clinical | Tohoku University | Diagnostic agents | 詳細 |
| Pittsburgh Compound B | [11C]PIB; [11C]6-OH-BTA-1; 11C-PIB | Phase 2 Clinical | Ge Healthcare, The University Of Utah, University Of Pittsburgh, Uppsala Universitet | Alcoholism; Alzheimer Disease; Brain Concussion; Breast Neoplasms; Dementia; Ovarian Neoplasms; Parkinson Disease | 詳細 |
| Zervimesine fumarate | SV-119; CT-1812 | Phase 2 Clinical | Cogrx | Alzheimer Disease; Cognition Disorders; Lewy Body Disease; Macular Degeneration | 詳細 |
| [18F]THK-5105 | [18F]THK-5105 | Phase 2 Clinical | Tohoku University | Alzheimer Disease | 詳細 |
| Edonerpic | T-817 MA | Phase 2 Clinical | Fujifilm Group, Toyama Chemical Co Ltd | Alzheimer Disease; Cognitive Dysfunction; Hepatic Insufficiency | 詳細 |
| ABvac-40 | ABvac-40 | Phase 2 Clinical | Araclon Biotech Sl | Alzheimer Disease; Cognitive Dysfunction | 詳細 |
| TML-6 | TML-6 | Phase 2 Clinical | Merry Life Biomedical Co Ltd | Alzheimer Disease | 詳細 |
| PHENOGENE-1A | Phase 2 Clinical | PhenoNet Inc | Alzheimer Disease; Amyotrophic Lateral Sclerosis | 詳細 | |
| PK-051 | PK051; PK-051 | Phase 2 Clinical | PharmaKure Ltd | Alzheimer Disease; Cognitive Dysfunction | 詳細 |
| PRI-002 | RD-2; PRI-002 | Phase 2 Clinical | Priavoid, PRInnovation GmbH | Alzheimer Disease; Cognitive Dysfunction | 詳細 |
| 18F-92 | 18F-92 | Phase 2 Clinical | First Affiliated Hospital Of Fujian Medical University | Alzheimer Disease | 詳細 |
| OAB-14 | OAB-14 | Phase 2 Clinical | Shenyang Pharmaceutical University | Alzheimer Disease | 詳細 |
| Mivelsiran | ALN-APP | Phase 2 Clinical | Sirna Therapeutics Inc | Alzheimer Disease; Cerebral Amyloid Angiopathy | 詳細 |
| SHR-1707 | SHR-1707 | Phase 2 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Alzheimer Disease | 詳細 |
| BEY-2153 | BEY-2153 | Phase 2 Clinical | Beyondbio Inc | Alzheimer Disease | 詳細 |
| Ezeprogind | AZP-2006 | Phase 2 Clinical | Alzprotect, Inserm | Alzheimer Disease; Supranuclear Palsy, Progressive | 詳細 |
| [18F]THK-5117 | [18F]THK-5117 | Phase 2 Clinical | Tohoku University | Alzheimer Disease | 詳細 |
| AD-35 | AD-35 | Phase 2 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Alzheimer Disease | 詳細 |
| APH-1105 | APH-1105 | Phase 2 Clinical | Aphios Corporation | Alzheimer Disease; Dementia | 詳細 |
| RIV-1061-IR | RIV-1061; RIV-1061-IR | Phase 1 Clinical | Revivo Therapeutics | Alzheimer Disease; Cognition Disorders | 詳細 |
| A ß antibody Fab | Phase 1 Clinical | Eli Lilly And Company | Alzheimer Disease | 詳細 | |
| MDR-1339 | DBT-1339; MDR-1339 | Phase 1 Clinical | Medifron | Alzheimer Disease | 詳細 |
| chimeric fusion protein (Attralus/University of Limoges) | AT-03 (Attralus) | Phase 1 Clinical | Universite De Limoges | Amyloidosis | 詳細 |
| ADx-001 | Phase 1 Clinical | University Of Houston | Alzheimer Disease; Dementia | 詳細 | |
| ALZ-101 | ALZ-101 | Phase 1 Clinical | Alzinova AB | Alzheimer Disease; Dementia | 詳細 |
| PRX-012 | PRX-012 | Phase 1 Clinical | Prothena | Alzheimer Disease | 詳細 |
| PMN-310 | huPMN-310; PMN-310 | Phase 1 Clinical | ProMIS Neurosciences Inc | Alzheimer Disease; Amyotrophic Lateral Sclerosis; Multiple System Atrophy | 詳細 |
| AK-152 | AK152; AK-152 | Phase 1 Clinical | Alzheimer Disease | 詳細 | |
| AA-001 | AA-001; AA001 | Phase 1 Clinical | Beijing Zhiyuan Hongsheng Biopharmaceutical Co Ltd | Alzheimer Disease; Cognitive Dysfunction | 詳細 |
| ION-269 | ION-269; ION269 | Phase 1 Clinical | Ionis Pharmaceuticals Inc | Alzheimer Disease; Down Syndrome | 詳細 |
| ALIA-1758 | ABBV-1758; ALIA-1758 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine | Alzheimer Disease | 詳細 |
| CM-383 | CM383; CM-383 | Phase 1 Clinical | Keymed Biosciences Co Ltd | Alzheimer Disease; Cognitive Dysfunction | 詳細 |
| AS-603 | S-603; AS-603; AS-S603 | Phase 1 Clinical | Amyloid Solution Inc | Alzheimer Disease | 詳細 |
| AV-1959R/AV-1980R | 1959R + 1980R; AV 1959R + AV 1980R | Phase 1 Clinical | Nuravax | Alzheimer Disease | 詳細 |
| Abeta42 antibody (Lilly) | Phase 1 Clinical | Eli Lilly And Company | Alzheimer Disease | 詳細 | |
| Anatabine citrate | RCP-006 | Clinical | Rock Creek, Roskamp Institute | Alzheimer Disease; Inflammation; Smoking Cessation; Thyroiditis, Autoimmune; Tobacco Use Disorder | 詳細 |
| 123I-ABC-577 | 123I-ABC-577 | Clinical | Nihon Medi-Physics Co Ltd | Diagnostic agents | 詳細 |
| Tarenflurbil spraygel (MIKA Pharma) | Clinical | Galen Ltd, Mika Pharma Gmbh | Arthritis, Rheumatoid; Dermatitis, Atopic; Inflammation; Pain; Skin Diseases | 詳細 |
市販薬剤に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Donanemab | LY-3002813-IV; LY-3002813; LY-3002813-SC | Approved | Eli Lilly And Company | Kisunla, 记能达 | United States | Alzheimer Disease | Eli Lilly And Company | 2024-07-02 | Alzheimer Disease; Brain Diseases; Central Nervous System Diseases; Cognition Disorders; Cognitive Dysfunction; Dementia; Mental Disorders; Nervous System Diseases; Neurocognitive Disorders; Neurodegenerative Diseases; Tauopathies | 詳細 |
| Flutemetamol (18F) | 18F-GE067; AH-110690; GE-067 | Approved | Ge Healthcare | Vizamyl | United States | Contrast agents | Ge Healthcare | 2013-10-25 | Alzheimer Disease; Atherosclerosis; Breast Neoplasms; Cognition Disorders; Cognitive Dysfunction; Contrast agents; Dementia; Diagnostic agents; Hydrocephalus, Normal Pressure | 詳細 |
| Inositol | 4L6452S749 | Approved | Nicosit | Anovulation; Anxiety; Bronchopulmonary Dysplasia; Carcinoma, Non-Small-Cell Lung; Depression; Diabetic Neuropathies; Glucose Intolerance; Hyperandrogenism; Infant, Newborn, Diseases; Insulin Resistance; Lung Neoplasms; Metabolic Diseases; Polycystic Ovary Syndrome; Precancerous Conditions; Premature Birth; Retinopathy of Prematurity | 詳細 | |||||
| Immune globulin 10% (Grifols) | KIg-10; TAL-05-0002 | Approved | Bayer AG | Gamunex, Gammaked | United States | Purpura, Thrombocytopenic, Idiopathic; Immunologic Deficiency Syndromes; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | null | 2003-08-27 | Agammaglobulinemia; Anemia, Sickle Cell; Anxiety Disorders; Autoimmune Diseases; Common Variable Immunodeficiency; Corneal Neovascularization; Coronavirus Disease 2019 (COVID-19); Immunologic Deficiency Syndromes; Kidney Failure, Chronic; Muscular Diseases; Myasthenia Gravis; Neuralgia; Obsessive-Compulsive Disorder; Pain; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Postural Orthostatic Tachycardia Syndrome; Primary Immunodeficiency Diseases; Purpura, Thrombocytopenic, Idiopathic; Reflex Sympathetic Dystrophy; Severe Combined Immunodeficiency; Tibial Fractures; Wiskott-Aldrich Syndrome | 詳細 |
| Florapronol (18F) | 18F-FC-119(S); 18F-FC-119S | Approved | Futurechem, Korea Institute Of Radiological And Medical Sciences | Alzavue | Alzheimer Disease | 詳細 | ||||
| Aducanumab | BIIB-037; NI-10; BART | Approved | Neurimmune Ag | ADUHELM | United States | Alzheimer Disease | Biogen Inc | 2021-06-07 | Alzheimer Disease; Cognitive Dysfunction; Dementia | 詳細 |
| Procaine Hydrochloride/Vitamin B6/Inositol | Approved | Arteriosclerosis; Dyspepsia; Menopausal symptoms; Neurocirculatory Asthenia | 詳細 | |||||||
| Inositol/Vitamin B1/Vitamin B2 | Approved | Liver Diseases | 詳細 | |||||||
| L-Lysine hydrochloride/Cyanocobalamin/Inositol | Approved | 兴邦 | Malnutrition | 詳細 | ||||||
| Immune Globulin Subcutaneous (Human) (Octapharma) | Approved | Octapharma | Cutaquig, Octanorm, Gammanorm | United States | Immunologic Deficiency Syndromes | null | 2018-08-02 | Dermatomyositis; Immunologic Deficiency Syndromes; Primary Immunodeficiency Diseases | 詳細 | |
| Florbetaben (18F) | AV-1; ZK-6013443; BAY-949172; 18F-AV-1; MNI-815; BAY 94-9172; UNII-TLA7312TOI; 18F-AV1/ZK; AV-1/ZK | Approved | Avid Radiopharmaceuticals Inc | 欧韦宁, Neuraceq | EU | Alzheimer Disease | Life Radiopharma Berlin Gmbh | 2014-02-20 | Alzheimer Disease; Amyloidosis; Contrast agents; Dementia; Down Syndrome; Hyponatremia; Immunoglobulin Light-chain Amyloidosis; Lewy Body Disease; Parkinson Disease; Supranuclear Palsy, Progressive | 詳細 |
| Lecanemab | BAN-2401 | Approved | Bioarctic Neuroscience | Leqembi, LEQEMBI, 乐意保 | United States | Alzheimer Disease | Eisai Inc | 2023-01-06 | Alzheimer Disease; Cognitive Dysfunction; Dementia | 詳細 |
| Florbetapir(18F) | MNI-798; AV-45 | Approved | Eli Lilly And Company | 艾美维, Amyvid | United States | Alzheimer Disease | Avid Radiopharmaceuticals Inc | 2012-04-06 | Alzheimer Disease; Cognitive Dysfunction; Contrast agents; Frontotemporal Dementia; Glioblastoma; Lewy Body Disease; Neurodegenerative Diseases; Parkinson Disease | 詳細 |